Skip to main content
. Author manuscript; available in PMC: 2017 Feb 9.
Published in final edited form as: Circulation. 2016 Jan 13;133(6):584–591. doi: 10.1161/CIRCULATIONAHA.115.019657

Table 1. Characteristics of SPS3 Participants by treatment group at baseline.

Overall Higher BP Lower BP
“Usual” “Intensive”

n 2610 1309 1301 P-value
Age (years) 63 (11) 64 (11) 63 (11) 0.34
Male 1655 (63%) 862 (66%) 793 (61%) 0.01
Race
 Non-Hispanic White 1300 (50%) 641 (49%) 659 (51%) 0.75
 Black 413 (16%) 205 (16%) 208 (16%)
 Hispanic 834 (32%) 430 (33%) 404 (31%)
 Other/multiple 63 (2%) 33 (3%) 30 (2%)
Region
 North America 1672 (64%) 835 (64%) 837 (64%) 0.87
 Latin America 647 (25%) 330 (25%) 317 (24%)
 Spain 291 (11%) 144 (11%) 147 (11%)
Smoking
 Current 506 (19%) 255 (19%) 251 (19%)
 Past 1069 (41%) 525 (40%) 544 (42%)
 Never 1035 (40%) 529 (40%) 506 (39%) 0.65
BMI (kg/m2) 29 (7) 29 (8) 29 (6) 0.27
Diabetes 950 (36%) 469 (36%) 481 (37%) 0.54
Hypertension 2337 (90%) 1176 (90%) 1161 (89%) 0.62
SBP (baseline) 143 (19) 144 (19) 142 (18) 0.10
SBP (3 mo) 133 (16) 137 (15) 130 (15) <.0001
SBP (9 mo) 132 (15) 137 (15) 127 (14) <.0001
eGFR (ml/min/1.73m2) 80 (19) 80 (18) 80 (19) 0.59
eGFR category at baseline:
 <60 410 (16%) 195 (15%) 215 (17%) 0.25
 >60 2198 (84%) 1113 (85%) 1085 (83%)

Data are presented as Mean (SD) or numbers (percent).

SBP=systolic blood pressure in mmHg

eGFR= glomerular filtration rate estimated by CKD Epi equation in ml/min/1.73m2

2 persons are missing creatinine data at baseline, but have at least two values at follow-up.